Vanguard Capital Management
ALGS icon

Vanguard Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Vanguard Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$988K Hold
175,543
– – ﹤0.01% 3557
2026
Q2 		$1.01M Sell
175,543
-2,719
-2% -$16.8K ﹤0.01% 3594
2026
Q1 		$1.32M Buy
+178,262
New +$1.35M ﹤0.01% 3488

Other funds holding ALGS

Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $18B AUM 27.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Quadrature Capital
Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

Vanguard Capital Management's ALGS Position: Q3 2026 in Review

Vanguard Capital Management held its Aligos Therapeutics (ALGS) position steady in Q3 2026 at 175,543 shares worth $988K. The position accounts for ﹤0.01% of the portfolio, ranked #3557.

Vanguard Capital Management first reported a position in ALGS in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.32M in Q1 2026. 20 funds tracked by Wall St. Rank hold ALGS as of Q3 2026.

  • Vanguard Capital Management held 175,543 shares of Aligos Therapeutics worth $988K as of Q3 2026.
  • Vanguard Capital Management left its Aligos Therapeutics share count unchanged in Q3 2026.
  • Aligos Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3557 holding.
  • Vanguard Capital Management first reported a position in Aligos Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Aligos Therapeutics position peaked at $1.32M in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.